D
Douglas Rizzo
Researcher at Medical College of Wisconsin
Publications - 7
Citations - 1066
Douglas Rizzo is an academic researcher from Medical College of Wisconsin. The author has contributed to research in topics: Transplantation & Survival rate. The author has an hindex of 6, co-authored 7 publications receiving 947 citations. Previous affiliations of Douglas Rizzo include Center for International Blood and Marrow Transplant Research.
Papers
More filters
Journal ArticleDOI
Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.
Sergio Giralt,Karen K. Ballen,Douglas Rizzo,Andreas Bacigalupo,Mary M. Horowitz,Marcelo C. Pasquini,Brenda M. Sandmaier +6 more
TL;DR: Although HCT professionals have not reached a consensus on what constitutes a RIC regimen, most accept currently used criteria and operational definitions, and these results support the continued use of current criteria for RIC regimens until a consensus statement can be developed.
Journal ArticleDOI
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study
Catherine Metayer,Rochelle E. Curtis,Julie M. Vose,Kathleen A. Sobocinski,Mary M. Horowitz,Smita Bhatia,Joseph W. Fay,Cesar O. Freytes,Steven C. Goldstein,Roger H. Herzig,Armand Keating,Carol B. Miller,Thomas J. Nevill,Andrew L. Pecora,Douglas Rizzo,Stephanie F. Williams,Chin Yang Li,Lois B. Travis,Daniel J. Weisdorf +18 more
TL;DR: The data show that type and intensity of pretransplantation chemotherapy with alkylating agents are important risk factors of MDS/AML following autotransplantations and Transplantation-related factors may also modulate this risk; however, the apparent contribution of high-dose TBI requires confirmation.
Journal ArticleDOI
Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
Carolyn A. Keever-Taylor,Christopher Bredeson,Fausto R. Loberiza,James T. Casper,Colleen A. Lawton,Douglas Rizzo,William H. Burns,David A. Margolis,David H. Vesole,Mary M. Horowitz,Mei-Jie Zhang,Mark B. Juckett,William R. Drobyski +12 more
TL;DR: The data indicate that there are quantitative as well as potential qualitative differences in outcome depending on the TCD method, and support the consideration of ABO match in donor selection, the preferential selection of CMV-positive donors for CMv-positive recipients, and the acceptance of 1 but not > or =2 Ag HLA MM donors.
Journal ArticleDOI
Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program.
Sergio Giralt,Brent R. Logan,Douglas Rizzo,Mei-Jie Zhang,Karen K. Ballen,Christos Emmanouilides,Rajneesh Nath,Pablo M. Parker,David L. Porter,Brenda Sandmaier,Edmund K. Waller,Juliet N. Barker,Steven Pavletic,Daniel J. Weisdorf +13 more
TL;DR: This analysis demonstrates that long-term survival and disease control can be obtained with URD progenitor cell transplantation after RIC conditioning, however, only prospective trials will define the optimal role of this therapy in patients with hematologic malignancies.
Journal ArticleDOI
Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission
Julie M. Vose,Douglas Rizzo,Jing Tao-Wu,James O. Armitage,Asad Bashey,Linda J. Burns,N. P. Christiansen,Cesar O. Freytes,Robert Peter Gale,John Gibson,Sergio Giralt,Roger H. Herzig,Charles F. LeMaistre,Philip L. McCarthy,Stephen D. Nimer,Finn Bo Petersen,David P. Schenkein,Peter H. Wiernik,Joseph Wiley,Fausto R. Loberiza,Hillard M. Lazarus,Koen van Biesen,Mary M. Horowitz +22 more
TL;DR: In multivariate analysis, chemotherapy resistance, increased lactic dehydrogenase at diagnosis, an interval of <12 months from diagnosis to relapse, age >or=40 years, and use of myeloid growth factors to accelerate posttransplantation bone marrow recovery were adverse predictors of survival.